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Abstract
Background: Hereditary hemorrhagic telangiectasia (HHT), also known as Rendu-Osler-Weber
syndrome, is an autosomal dominant disorder which is clinically characterised by recurrent
epistaxis, mucocutaneous telangiectasia and visceral arteriovenous malformations. Genetic linkage
studies identified two genes primarily related to HHT: endoglin (ENG) on chromosome 9q33-34
and activin receptor-like kinase1 (ACVRL1) on chromosome 12q13. We have screened a total of 41
unselected German patients with the suspected diagnosis of HHT. Mutation analysis for the ENG
and ACVRL1 genes in all patients was performed by PCR amplification. Sequences were then
compared to the HHT database http://www.hhtmutation.org sequences of the ENG  mRNA
(accession no. BC014271.2) and the ACVRL1 mRNA (accession no. NM000020.1).
Results: We identified 15 different mutations in 18 cases by direct sequencing. Among these
mutations, one novel ENG mutation could be detected which has not yet been described in the
literature before. The genotype-phenotype correlation was consistent with a higher frequency of
pulmonary arteriovenous malformations in patients with ENG mutations than in patients with
ACVRL1 mutations in our collective.
Conclusion: For rapid genotyping of mutations and SNPs (single nucleotide polymorphisms) in
ENG and ACVRL1, allele-specific PCR methods with sequence-specific primers (PCR-SSP) were
established and their value analysed.
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Background
Hereditary hemorrhagic telangiectasia (HHT,
MIM#18730), also known as Rendu-Osler-Weber syn-
drome, is an autosomal dominant disorder of the fibrov-
ascular tissue. Worldwide, HHT has a prevalence of 1 in
10.000 individuals [1,2]. This multi-systemic angiogenic
disorder is clinically characterized by severe and recurrent
hemorrhages due to epistaxis, mucocutaneous tel-
angiectasia and arteriovenous malformations. Vascular
lesions are present in two forms, either as telangiectases
on the skin as well as the inner lining of the mouth, nose
and gastrointestinal tract (GI-tract) and/or as direct arteri-
ovenous shunts most commonly seen in the lung
(PAVM), brain (CAVM) and liver (HAVM) [3-9]. Electron
microscopy studies on lesion biopsies revealed that
dilated postcapillary venules connect directly to arterioles
without intervening capillary bed [10,11]. As a result,
these vascular lesions can be the cause for severe compli-
cations involving gastrointestinal bleedings, the risk of
embolism, stroke and abscesses [12].
Till now, HHT can not be cured. The treatment of HHT
patients remains symptomatic or has preventive character.
The Curaçao criteria are in clinical use for diagnosis of
HHT [13]. However, the clinical manifestations of HHT
can be very heterogeneous, both between families and
among members of the same family, making the diagno-
sis of the disease at times very difficult.
In the 90s, genetic linkage studies revealed the two major
types of disease, HHT1 and HHT2, caused by mutations in
the ENG (endoglin) and ACVRL1 genes. The first locus
(HHT type 1) was mapped to chromosome 9q33-34
[14,15], where the 40 kb endoglin (ENG, OMIM 187300)
was defined as the affected gene [16], also associated with
a high prevalence of pulmonary arteriovenous malforma-
tions [17]. The second locus (HHT type 2) mapping to
chromosome 12q was identified as the 15 kb activin
receptor-like kinase-1 gene (ACVRL1, OMIM 600376)
[18,19]. It is characterised by a lower incidence of pulmo-
nary and cerebral arteriovenous malformations than
HHT1, but has a higher incidence of liver manifestation
[17,20]. The corresponding endoglin and ALK-1 proteins
are specific endothelial receptors of the transforming
growth factor beta superfamily essential for maintaining
vascular integrity [21,22]. Many mutations have been
identified in ENG  and ACVRL1  genes and support the
haploinsufficiency model for HHT [23]. In recent studies,
two more genes have been implicated in HHT, which have
not yet been identified, the HHT3 gene on chromosome 5
[24], and the HHT4 gene on chromosome 7 [25]. In addi-
tion, SMAD4 mutations mapping to chromosome 18
have been observed in patients with a combined syn-
drome of juvenile polyposis and HHT (JPHT) [26].
In this study, we report mutational analysis of the two
main genes ENG and ACVRL1 in a German population
affected by HHT. We describe a novel mutation in the
ENG gene in HHT patients which has not been described
before. Furthermore, we determine the value of allele-spe-
cific PCR for rapid genotyping.
Methods
Patients and controls
Anti-coagulated peripheral blood samples were obtained
from 41 patients of German origin with tentative diagno-
sis of HHT at the Department of ORL, Head and Neck Sur-
gery, University Hospital Mannheim, and from 768
healthy blood donors as a control group from the Institute
of Transfusion Medicine and Immunology, Mannheim
(Additional file 1). The HHT patients comprised 4 small-
sized families (3 persons each) and 29 single cases (Fig.
1). Information on the clinical data including the medical
history, physical examination and diagnostic screening
was obtained in personal interviews with the affected
individuals and from their patient records with all the
data being documented in an HHT database. According to
the Curaçao criteria, diagnosis for HHT included the pres-
ence of three out of four key symptoms: recurrent
epistaxis, telangiectasia, hereditary with an affected first
degree relative and visceral involvement [13] (Additional
file 2). An informed consent was obtained from each indi-
vidual and from parents of patients younger than 18 years
according to the approval of the Ethic Committee of the
University of Mannheim.
Isolation of DNA
DNA was extracted from anti-coagulated peripheral blood
samples using a commercial DNA isolation kit (QIAamp
DNA blood mini kit; Qiagen, Hilden, Germany) accord-
ing to the standard protocol.
Sequencing of ENG and ACVRL1 exons
All coding exons and flanking intronic sequences of the
ENG and ACVRL1 genes were PCR amplified using prim-
ers published previously [27,28]. PCR was performed in a
total volume of 50 μl including 100 ng DNA, 0.5 μM each
primer, 200 μM each dNTP, standard PCR buffer (Qiagen)
and 1 U HotStar Taq DNA polymerase (Qiagen). The
cycling parameters were as follows: initial denaturation
for 15 min at 95°C; 35 cycles with 20 sec. at 94°C, 30 sec.
at 60°C and 60 sec. at 72°C; final extension for 5 min at
72°C. After the PCR, products were run on 2% agarose
gels. The 15 exons of ENG and the 9 exons of ACVRL1
were sequenced in 41 patients with HHT using Thermose-
quenase reagents (GE Healthcare Amersham), IRD700
and IRD800 labelled primers and an automated system
(NEN® Global IR2 DNA Sequencer; LI-COR inc., Lincoln,
NE, USA). Sequences were compared to the HHT databaseBMC Medical Genetics 2009, 10:53 http://www.biomedcentral.com/1471-2350/10/53
Page 3 of 9
(page number not for citation purposes)
http://www.hhtmutation.org sequences of the ENG
mRNA (accession no. BC014271.2) and the ACVRL1
mRNA (accession no. NM000020.1).
PCR-SSP typing of SNPs
For rapid genotyping of the mutations and SNPs in ENG
and ACVRL1, allele-specific PCR methods with sequence-
specific primers (PCR-SSP) were established. Specific
primer sequences and sizes of PCR products are given in
Additional file 3. Part of the β-globin locus was amplified
as an internal control PCR fragment (540 bp). According
to a published PCR-SSP protocol [29,30], 20 ng DNA were
subjected to 10 μl PCR reactions including 0.5 μM each
allele-specific primers, 0.1 μM each internal control
primer, standard PCR buffer (Qiagen), 200 μM each dNTP
and 0.5 units Taq DNA polymerase (Qiagen). The cycling
conditions were: 2 min initial denaturation at 94°C, fol-
lowed by 10 cycles with 20 s denaturation at 94°C and 1
min annealing/extension at 65°C, followed by 20 cycles
with 20 s duration at 94°C, 1 min annealing at 61°C and
30 s extension at 72°C. Amplification products were sep-
arated on 2% agarose gels containing 0.5 ng/ml ethidium
bromide in a rapid agarose gel electrophoresis (RAGE;
Cascade Biologics, Inc., Portland, OR, USA) chamber for
5 min at 25 V/cm. Results were obtained by visual inspec-
tion of the gels and were documented by using a UV doc-
umentation device with CCD camera (UVP, Inc., Upland,
CA, USA).
Results
The 15 coding exons of the ENG gene and the 9 exons of
the  ACVRL1  gene including flanking intron sequences
were PCR amplified and sequenced from 41 patients with
HHT. The sequence data were compared to each other and
to the ENG and ACVRL1 sequences published in data-
bases (HHT Mutation Database: http://www.hhtmuta
tion.org). Mutations could be detected in 18 cases
(43.9%).
Sequence analysis of ENG
ENG mutations
We identified 5 different ENG mutations in 6 out of 41
HHT patients. The 5 different ENG mutations represented:
1 deletion, 1 insertion, 2 splice site mutations and 1 mis-
sense mutation (Additional file 4). In our study, mutation
c.816+2T>C was detected in 2 related cases. One novel
ENG mutation was detected in exon 10 (c.1384insT) caus-
ing a frameshift (p.Gln462fs) which has not yet been
Pedigree of the four small-sized HHT families Figure 1
Pedigree of the four small-sized HHT families. White square and white circle = unaffected, grey square and grey circle = 
affected, X = DNA available, # = Pat.-no.
I
II
12
12 3 4 #12 #41 #13
Family F2
I
II
III
Family F4
2 1
2 13 4
2
1
3
#37 #31
#33
I
II
1
1
2
23
#09
#04 #01
Family F1
I
II
2
2
1
13 4
#24
#19 #28
Family F3
xx
x
xx x
xx
x
x
xxBMC Medical Genetics 2009, 10:53 http://www.biomedcentral.com/1471-2350/10/53
Page 4 of 9
(page number not for citation purposes)
listed in the HHT gene database before. Altogether, all of
the mutations found in ENG were detected in exons cod-
ing for the extracellular protein-domain. No mutations
were detected in the region coding for the intracellular
domain (Fig. 2).
Polymorphisms in the ENG gene
The 5 different polymorphisms and their relative frequen-
cies identified in the ENG gene are presented in Addi-
tional file 5. A previously reported G to A substitution at
position 207 of exon 2 (c.207G>A) was observed in 12
out of 41 HHT patients (29.3%). Two patients carried a
c.1844C>T polymorphism in exon 13 (4.8%). At position
1029 (c.1029C>T) of exon 8, a C to T change was
observed in 7 HHT patients (17%). A c.1347A>G poly-
morphism in exon 10 and a c.1771G>A polymorphism in
exon 13 was observed in one HHT patient (2.4%).
Sequence analysis of ACVRL1
ACVRL1 mutations
Ten different ACVRL1 mutations could be identified in 12
out of 41 HHT patients, including 2 deletions, 2 inser-
tions, 1 splice site mutation and 5 missense mutations
(Additional file 6). The insertion c.144_145insG
(p.Ala49fs) was detected in 2 members of the same fam-
ily, whereas the missense mutation c.1120C>T
(p.Arg374Trp) was detected in 2 unrelated cases. Half of
the HHT2 associated ACVRL1 mutations consisted of sin-
gle base substitutions, leading to amino acid changes.
More than 75% of all ACVRL1 mutations were detected in
exons coding for the intracellular domain (Fig. 3). Espe-
cially four out of five missense mutations (80%) were
found in the receptor domain or the kinase domain,
mainly affecting exon 8. No mutations were detected in
the region coding for the transmembrane domain.
PCR-SSP typing for ENG and ACVRL1 mutations
Further investigation on allele and genotype frequencies
focused on the mutations identified in our cohort of HHT
patients. PCR-SSP systems could be established for all
ACVRL1 mutations and all ENG mutations. A panel of
DNA samples from HHT patients with different muta-
tions was selected on the basis of the sequencing data and
was used to validate all 15 PCR-SSP systems. The geno-
types were estimated on the basis of the presence or the
absence of the allele-specific PCR products (Fig. 4). All of
the 41 HHT samples were retyped by PCR-SSP and data
were compared to sequencing data. We could achieve
100% concordance of data, i.e. DNA samples with muta-
tion revealed a positive PCR signal in the corresponding
PCR-SSP system and DNA samples without mutation
were negative in all 15 PCR-SSP systems. In addition, the
15 PCR-SSP systems were applied for genotyping of the
ENG and ACVRL1 mutations in 768 healthy blood donor
controls. None of the healthy control individuals showed
an ENG or ACVRL1 mutation indicating the specificity of
the gene variants for the HHT phenotype.
Phenotype-Genotype Correlation
Diagnosis of HHT in an individual required that they met
three or more of the following four Curaçao criteria: 1)
spontaneous and recurrent epistaxis, 2) mucocutaneous
Distribution of mutations in the ENG gene Figure 2
Distribution of mutations in the ENG gene. Novel mutation is given in bold.
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telangiectasias, 3) organ manifestation with arteriovenous
malformations (AVMs) including pulmonary, cerebral,
hepatic, gastrointestinal and/or 4) hereditary with a first-
degree relative with HHT [13]. All patients included in
this study either met the criteria for manifest clinical diag-
nosis or suspected clinical diagnosis of HHT with at least
three or two criteria present. Altogether, 71% of the
patients (29 out of 41) had a manifest HHT diagnosis. All
of the patients had as main clinical symptom recurrent
epistaxis and a positive family history of HHT, followed
by telangiectasias in 65.8% and AVMs of any type in 56%
of the cases. Of the 41 patients tested, 18 patients were
found to have sequence alterations, with 6 patients show-
ing mutations for ENG and 12 patients revealing muta-
tions for ACVRL1. The genotype-phenotype correlation of
all HHT patients with confirmed mutation is given in
Additional file 7.
Discussion
Presently,  ENG  (endoglin) on chromosome 9q33-q34
and  ACVRL1  (activin-receptor-like kinase) on chromo-
some 12q13 are the two genes primarily implicated in the
development of Hereditary Hemorrhagic Telangiectasia
(HHT). In literature, frequent mutations in both genes
have been detected in different case studies indicating a
common occurrence of ENG and ACVRL1 DNA changes
in patients with HHT [27,28].
In a consecutive series of 41 patients, we performed clini-
cal genetic testing for the two major types of disease,
HHT1 and HHT2, caused by mutations in the ENG and
ACVRL1 gene sequence for HHT. The series included 29
patients with clinical diagnosis of HHT who met three or
more clinical features and 12 patients with suspected diag-
nosis with two clinical features according to the Curaçao
criteria. The mutation detection rate in our series of 41
German patients was 44%. Based on the Curaçao criteria,
15 of the 18 patients (83%) with a mutation had a mani-
fest clinical HHT diagnosis, with the remaining 3 patients
(17%) fulfilling two criteria. This rate is similar to other
studies which have been consistently described in litera-
ture [17,27,28]. Most of the mutations were found in the
ACVRL1 gene with a total of 10 different mutations in 12
HHT patients whereas a total of 5 mutations were identi-
fied in the coding sequence of the ENG gene in 6 individ-
uals. Most of the ENG mutations were widely distributed
throughout the gene, not indicating any special hot spot
areas within the gene. Out of five detected DNA changes,
four mutations had been described previously as muta-
tions in the HHT mutation database or recently been pub-
Distribution of mutations in the ACVRL1 gene Figure 3
Distribution of mutations in the ACVRL1 gene.
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lished [2,5,20,27,31-35]. The alterations included mainly
nucleotide substitutions such as missense, splice site and
frameshift mutations. In spite of the fact that only a small
series of HHT patients was investigated in this study, one
novel ENG mutation c.1384insT (p.Gln462fs) could be
detected which had not been described before in the HHT
mutation database. Unlike ENG, 50% of the mutations in
the ACVRL1 gene were missense substitutions. Similar
results had been published by Abdalla et al. who analysed
all 123 till then known mutations of ACVRL1. In their
study overview they could also register more than half
(53%) of the mutations in the ACVRL1 gene as missense
mutations [36,37]. As previously described in other HHT
families, the frequency of ACVRL1 mutations was highest
in exon 8 which might be an indicator for mutation
hotspots. The other mutations c.144_145insG
(p.Ala49fs), c.200G>A (p.Arg67Gln), c.540_541insA
(p.Asp181fs), c.673_674delAG (p.Ser225fs),
c.696_698delCTC (p.Ser233del), c.1346C>T
(p.Pro449Leu) and c.1377+1G>A in ACVRL1  were
already described by other workgroups, mostly located in
the intracellular kinase domain of the gene [28,35,37-40].
Only two already known mutations could be detected in
the extracellular domain of the gene. However, large dele-
tions and insertions in ENG and ACVRL1 were not ana-
lyzed which could explain the low detection rate of
mutations in our study compared to other studies
described in literature [28,32,36].
As far as the genotype-phenotype correlation is con-
cerned, most of the pulmonary arteriovenous malforma-
tions (PAVMs) in our study were detected in HHT patients
Representative results from PCR-SSP analysis of different ENG (A) and ACVRL1 (B) mutations Figure 4
Representative results from PCR-SSP analysis of different ENG (A) and ACVRL1 (B) mutations. Three of the 5 
PCR-SSP systems for ENG mutations and 4 of the 10 PCR-SSP systems for ACVRL1 mutations are shown as examples. The spe-
cificity of PCR-SSP for the corresponding mutations was given by the absence of the specific PCR product in healthy controls 
(each lane 1) and presence of the PCR product in the HHT patient (each lane 2). The internal control fragment of 540 bp in 
size (arrow head) was present in each reaction (or at least where the PCR-SSP product was absent).
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with mutations for ENG. This phenomenon has already
been described by previous studies given in literature, stat-
ing that mutations of ENG are mainly observed in HHT
type 1 with an incidence of up to 40% for PAVMs, whereas
mutations of ALK1 are primarily observed in HHT type 2
with an incidence of only 14% for PAVMs, which clini-
cally distinguishes these two types of mutation
[3,7,28,36]. Liver manifestations were more frequent in
patients with ACVRL1 mutations, whereas manifestations
of the skin and the GI-tract were seen equally distributed
amongst HHT patients with ENG and ACVRL1 mutations.
Many studies report a mutation detection rate of up to
92% [27,28,33]. However, in our study we were able to
identify only 43.9% of disease-causing mutations in a
series of 41 HHT patients. The difference in sensitivity
may result from several factors, including a very heteroge-
neous cohort of patients in terms of locations and initial
physician involved, and because patients with only 2
Curaçao criteria were included in the study. In addition,
only ENG and ACVRL1 genes were screened for muta-
tions, but in some cases, mutations in SMAD4, HHT3 and
HHT4 loci may be responsible for the clinical symptoms
[24-26].
In daily clinical routine, the diagnosis of HHT is primarily
based on the clinical findings according to the Curaçao
criteria. Nevertheless, in many cases clinical diagnostic is
at times very difficult due to the heterogeneous outcome
and manifestation of the disease. This fact asks for addi-
tional diagnostic tools which facilitate the daily clinical
work. Already in the past, many studies could show that
the molecular characterization of HHT enables to predict
the diagnosis before the manifestation of clinical symp-
toms. The results of the study reflect the very high and het-
erogenic distribution and allocation of mutations in HHT.
With an allele-specific PCR technique (PCR-SSP) we could
establish a diagnostic testing device for rapid genotyping
of mutations. The exon sequencing of ENG and ACVRL1
confirmed the previously described polymorphisms and
outlined one novel mutation Gln462fs in exon 10 of ENG
gene. The PCR-SSP technique can easily be performed
with standard laboratory equipment and may help to
minimize costs for genetic testing in the routine diagnosis
of family members of HHT patients with known muta-
tions.
Conclusion
In summary, this study is a further contribution to the
determination of already known ENG and ACVRL1 muta-
tions as well as the detection of one novel ENG mutation
in HHT. Next to the Curaçao criteria, genetic analysis cer-
tainly contributes as an essential tool to a reliable diagno-
sis of clinically affected HHT patients and clinically un-
symptomatic HHT patients, thus helping to take early pre-
ventive measures even before the occurrence of first clini-
cal symptoms. The PCR-SSP technique could facilitate this
high task of genetic analysis in routine HHT diagnostics
and underlines the importance of using molecular diag-
nosis for early identification of individuals carrying muta-
tions and being at risk of vascular complications.
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